AstraZeneca plc’s (AZN) “Hold” Rating Reiterated at Liberum Capital
Liberum Capital reissued their hold rating on shares of AstraZeneca plc (LON:AZN) in a research note published on Wednesday. The brokerage currently has a GBX 5,000 ($65.98) price target on the biopharmaceutical company’s stock.
A number of other equities research analysts have also recently issued reports on the stock. Shore Capital reaffirmed a hold rating on shares of AstraZeneca plc in a research note on Tuesday. UBS Group AG (USA) set a GBX 4,550 ($60.04) price objective on shares of AstraZeneca plc and gave the company a neutral rating in a research note on Monday, October 23rd. Morgan Stanley set a GBX 4,700 ($62.02) price objective on shares of AstraZeneca plc and gave the company a neutral rating in a research note on Friday, October 20th. J P Morgan Chase & Co set a GBX 4,500 ($59.38) price objective on shares of AstraZeneca plc and gave the company a neutral rating in a research note on Wednesday, October 18th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a sell rating and issued a GBX 3,800 ($50.15) price objective on shares of AstraZeneca plc in a research note on Tuesday, October 17th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of GBX 5,183.55 ($68.40).
Shares of AstraZeneca plc (LON:AZN) opened at GBX 5,180 ($68.36) on Wednesday.
ILLEGAL ACTIVITY WARNING: This report was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/astrazeneca-plcs-azn-hold-rating-reiterated-at-liberum-capital/1677790.html.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.